Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Sex differences in cancer outcomes across the range of eGFR.
Nephrol Dial Transplant. 2024 Mar 9:gfae059. doi: 10.1093/ndt/gfae059. Online ahead of print.
Nephrol Dial Transplant. 2024.
PMID: 38460949
Obesity is not associated with progression to end stage renal disease in patients with biopsy-proven glomerular diseases.
Elyan BMP, Lees JS, Gillis KA, Mackinnon B, Fox JG, Geddes CC, McQuarrie EP.
Elyan BMP, et al.
BMC Nephrol. 2019 Jul 2;20(1):237. doi: 10.1186/s12882-019-1434-7.
BMC Nephrol. 2019.
PMID: 31266462
Free PMC article.
Item in Clipboard
The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes.
Lees JS, Elyan BMP, Herrmann SM, Lang NN, Jones RJ, Mark PB.
Lees JS, et al. Among authors: elyan bmp.
Nephrol Dial Transplant. 2023 May 4;38(5):1071-1079. doi: 10.1093/ndt/gfac011.
Nephrol Dial Transplant. 2023.
PMID: 35090037
Free PMC article.
Review.
Item in Clipboard
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, Tomlinson LP, Lang NN, Mark PB.
Lees JS, et al. Among authors: elyan bmp.
Nephrol Dial Transplant. 2023 Jun 30;38(7):1666-1681. doi: 10.1093/ndt/gfac305.
Nephrol Dial Transplant. 2023.
PMID: 36318455
Free PMC article.
Item in Clipboard
Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review.
Elyan BMP, Rankin S, Jones R, Lang NN, Mark PB, Lees JS.
Elyan BMP, et al.
Kidney Med. 2023 May 16;5(7):100672. doi: 10.1016/j.xkme.2023.100672. eCollection 2023 Jul.
Kidney Med. 2023.
PMID: 37492115
Free PMC article.
No abstract available.
Item in Clipboard
Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials.
Rankin S, Elyan B, Jones R, Venugopal B, Mark PB, Lees JS, Petrie MC, Lang NN.
Rankin S, et al.
JACC CardioOncol. 2024 Feb 27;6(2):267-279. doi: 10.1016/j.jaccao.2023.12.010. eCollection 2024 Apr.
JACC CardioOncol. 2024.
PMID: 38774021
Free PMC article.
Item in Clipboard
Cite
Cite